Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease

Journal of Clinical Oncology

Volumn 31, Issue 35, 2013, Pages 4416-4423

  Hamadani, Mehdi ^a   Gibson, Laura F ^a   Remick, Scot C ^a   Wen, Sijin ^a   Petros, William ^a   Tse, William ^a   Brundage, Kathleen M ^a   Vos, Jeffrey A ^a   Cumpston, Aaron ^a   Bunner, Pamela ^a   Craig, Michael D ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ATORVASTATIN; CORTICOSTEROID; FLUCONAZOLE; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 17; INTERLEUKIN 2; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS; VALACICLOVIR; CYTOKINE; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ABSCESS; ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANKLE EDEMA; ARTICLE; BACTEREMIA; BK VIRUS INFECTION; CANCER SURVIVAL; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DONOR; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; ENGRAFTMENT; FATIGUE; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEART PALPITATION; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IRON OVERLOAD; LIVER DYSFUNCTION; MALE; MEDICATION COMPLIANCE; MORTALITY; MUCOSA INFLAMMATION; MYALGIA; MYCOSIS; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPHYLAXIS; PROSPECTIVE STUDY; RELAPSE; SHORT COURSE THERAPY; SIBLING; STAPHYLOCOCCUS AUREUS; TREATMENT DURATION; VIRUS REACTIVATION; ALLOTRANSPLANTATION; BACTERIAL INFECTIONS; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; FEASIBILITY STUDY; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; IMMUNOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; SURVIVAL; TREATMENT OUTCOME; VIRUS DISEASES; YOUNG ADULT; BACTERIAL INFECTION; DRUG EFFECT; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; METHODOLOGY; VIRUS INFECTION;

ADMINISTRATION, ORAL; ADULT; AGED; BACTERIAL INFECTIONS; CYTOKINES; FEASIBILITY STUDIES; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRROLES; SIBLINGS; SURVIVAL ANALYSIS; TISSUE DONORS; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIRUS DISEASES; YOUNG ADULT;

EID: 84894066201     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.50.8747     Document Type: Article

References (41)

1. Deeg HJ: How I treat refractory acute GVHD. Blood 109:4119-4126, 2007 (Pubitemid 46743372)
2. Jagasia M, Arora M, Flowers ME, et al: Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 119:296-307, 2012
3. Ratanatharathorn V, Nash RA, Przepiorka D, et al: Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation Blood 92:2303-2314, 1998 (Pubitemid 28452971)
4. Shlomchik WD, Couzens MS, Tang CB, et al: Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285:412-415, 1999 (Pubitemid 29343964)
5. Ferrara JL, Deeg HJ: Graft-versus-host disease. N Engl J Med 324:667-674, 1991
6. Lin MT, Storer B, Martin PJ, et al: Relation of an interleukin-10 promoter polymorphism to graftversus- host disease and survival after hematopoieticcell transplantation. N Engl J Med 349:2201-2210, 2003 (Pubitemid 37485136)
7. Lin MT, Storer B, Martin PJ, et al: Genetic variation in the IL-10 pathway modulates severity of acute graft-versus-host disease following hematopoietic cell transplantation: Synergism between IL-10 genotype of patient and IL-10 receptor beta genotype of donor. Blood 106:3995-4001, 2005 (Pubitemid 41739044)
8. Holler E, Roncarolo MG, Hintermeier-Knabe R, et al: Prognostic significance of increased IL-10 production in patients prior to allogeneic bone marrow transplantation. Bone Marrow Transplant 25:237-241, 2000 (Pubitemid 30103011)
9. Reshef R, Luger SM, Hexner EO, et al: Blockade of lymphocyte chemotaxis in visceral graft-versushost disease. N Engl J Med 367:135-145, 2012
10. Broady R, Levings MK: Graft-versus-host disease: Suppression by statins. Nat Med 14:1155- 1156, 2008
11. Youssef S, Stuve O, Patarroyo JC, et al: The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420: 78-84, 2002 (Pubitemid 35291443)
12. Fowler DH, Kurasawa K, Husebekk A, et al: Cells of Th2 cytokine phenotype prevent LPSinduced lethality during murine graft-versus-host reaction: Regulation of cytokines and CD8 lymphoid engraftment. J Immunol 152:1004-1013, 1994
13. Foley JE, Mariotti J, Ryan K, et al: Th2 cell therapy of established acute graft-versus-host disease requires IL-4 and IL-10 and is abrogated by IL-2 or host-type antigen-presenting cells. Biol Blood Marrow Transplant 14:959-972, 2008
14. Krenger W, Snyder KM, Byon JC, et al: Polarized type 2 alloreactive CD4 and CD8 donor T cells fail to induce experimental acute graft-versushost disease. J Immunol 155:585-593, 1995
15. Shimabukuro-Vornhagen A, Liebig T, von Bergwelt-Baildon M: Statins inhibit human APC function: Implications for the treatment of GVHD. Blood 112:1544-1545, 2008
16. Greenwood J, Steinman L, Zamvil SS: Statin therapy and autoimmune disease: From protein prenylation to immunomodulation. Nat Rev Immunol 6:358-370, 2006
17. Mausner-Fainberg K, Luboshits G, Mor A, et al: The effect of HMG-CoA reductase inhibitors on naturally occurring CD4 CD25 T cells. Atherosclerosis 197:829-839, 2008 (Pubitemid 351417882)
18. Edinger M, Hoffmann P, Ermann J, et al: CD4 CD25 regulatory T cells preserve graftversus- tumor activity while inhibiting graft-versushost disease after bone marrow transplantation. Nat Med 9:1144-1150, 2003 (Pubitemid 37173698)
19. Zeiser R, Youssef S, Baker J, et al: Preemptive HMG-CoA reductase inhibition provides graftversus- host disease protection by th-2 polarization while sparing graft-versus-leukemia activity. Blood 110:4588-4598, 2007 (Pubitemid 351377828)
20. Hamadani M, Awan FT, Devine SM: The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation. Blood 111:3901-3902, 2008
21. Rotta M, Storer BE, Storb R, et al: Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 16:1463-1466, 2010
22. Rotta M, Storer BE, Storb RF, et al: Donor statin treatment protects against severe acute graftversus- host disease after related allogeneic hematopoietic cell transplantation. Blood 115:1288-1295, 2010
23. Przepiorka D, Weisdorf D, Martin P, et al: 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 15:825-828, 1995
24. Filipovich AH, Weisdorf D, Pavletic S, et al: National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11:945-956, 2005 (Pubitemid 41754712)
25. Gooley TA, Leisenring W, Crowley J, et al: Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 18:695-706, 1999 (Pubitemid 29126745)
26. American Society for Blood and Marrow Transplantation: Standard criteria. http://www.asbmt.org/ displaycommon.cfm?an-1&subarticlenbr-35
27. Pidala J, Kim J, Jim H, et al: A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica 97: 1882-1889, 2012
28. Hamadani M, Craig M, Phillips GS, et al: Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning. Hematol Oncol 29:202-210, 2011
29. Seebach JD, Stussi G, Passweg JR, et al: ABO blood group barrier in allogeneic bone marrow transplantation revisited. Biol Blood Marrow Transplant 11:1006-1013, 2005 (Pubitemid 41754719)
30. Koreth J, Stevenson KE, Kim HT, et al: Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. J Clin Oncol 30:3202-3208, 2012
31. Hori A, Kanda Y, Goyama S, et al: A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease. Transplantation 79:372- 374, 2005 (Pubitemid 40299550)
32. Li JJ, Fang CH: Effects of 4 weeks of atorvastatin administration on the antiinflammatory cytokine interleukin-10 in patients with unstable angina. Clin Chem 51:1735-1738, 2005
33. Hernandez C, Francisco G, Ciudin A, et al: Effect of atorvastatin on lipoprotein (a) and interleukin- 10: A randomized placebo-controlled trial. Diabetes Metab 37:124-130, 2011
34. Liu Y, Jiang H, Liu W, et al: Effects of fluvastatin therapy on serum interleukin-18 and interleukin-10 levels in patients with acute coronary syndrome. Acta Cardiol 65:285-289, 2010
35. Tseng LH, Storer B, Petersdorf E, et al: IL10 and IL10 receptor gene variation and outcomes after unrelated and related hematopoietic cell transplantation. Transplantation 87:704-710, 2009
36. Ding L, Linsley PS, Huang LY, et al: IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 151:1224-1234, 1993 (Pubitemid 23219258)
37. Levings MK, Sangregorio R, Galbiati F, et al: IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells. J Immunol 166: 5530-5539, 2001 (Pubitemid 32374175)
38. Newman CB, Palmer G, Silbershatz H, et al: Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol 92:670-676, 2003 (Pubitemid 37103016)
39. Wagner JE, Thompson JS, Carter SL, et al: Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell depletion trial): A multi-centre, randomised phase II-III trial. Lancet 366:733-741, 2005 (Pubitemid 41207235)
40. Bacigalupo A, Lamparelli T, Bruzzi P, et al: Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 98:2942-2947, 2001
41. Lee SJ, Klar N, Weeks JC, et al: Predicting costs of stem-cell transplantation. J Clin Oncol 18: 64-71, 2000 (Pubitemid 30036337)